Vikram Purohit
Stock Analyst at Morgan Stanley
(0)
# 4731
Out of 5,253 analysts
202
Total ratings
25.81%
Success rate
-19.76%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Zenas BioPharma | Maintains: Overweight | 40 35 | 6.01 | 482.36% | 2 | Dec 11, 2024 | |
Incyte | Maintains: Equal-Weight | 64 69 | 73.52 | -6.15% | 23 | Oct 30, 2024 | |
Foghorn Therapeutics | Maintains: Equal-Weight | 6 9 | 4.07 | 121.13% | 9 | Sep 24, 2024 | |
Genmab | Maintains: Equal-Weight | 31 31 | 19.27 | 60.87% | 2 | Sep 11, 2024 | |
Acelyrin | Maintains: Equal-Weight | 13 6 | 1.95 | 207.69% | 7 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 59 64 | 56.12 | 14.04% | 6 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | 3.63 | 92.84% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 116 140 | 127.25 | 10.02% | 18 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 90 115 | 103.25 | 11.38% | 18 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 7 | n/a | n/a | 16 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 15 16 | 6.09 | 162.73% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 3.68 | 715.22% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 22 | 7.37 | 198.51% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 10 | 13.79 | -27.48% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 46 6 | 1.97 | 204.57% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 43 42 | 7.47 | 462.25% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 10 | n/a | n/a | 4 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 8 11 | 7.16 | 53.63% | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 23 | 2.09 | 976.56% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 60 30 | n/a | n/a | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 3 | n/a | n/a | 2 | Jan 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 38 41 | 40.52 | 1.18% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 120 40 | 24.98 | 60.13% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 13 | 1.61 | 707.45% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 39 38 | 24.2 | 57.02% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 24 20 | 13.37 | 49.59% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 11 10 | 9.74 | 2.67% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 7 | 12.13 | -42.29% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 2.43 | 805.35% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 25 60 | n/a | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 40 20 | 4.23 | 372.81% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | n/a | n/a | n/a | 2 | Mar 3, 2020 |